[ad_1]
Packages of the weight-loss drug Wegovy from the pharmaceutical firm Novo Nordisk lie on the gross sales counter in a Danish pharmacy.
Stefan Trumpf | Image Alliance | Getty Photos
The European Medicines Company is to undertake a assessment into a variety of medicine used to deal with weight problems and diabetes, in accordance with Reuters, after it was reported some sufferers had skilled ideas of suicide or self-harm.
Reuters stated Monday that the regulator was Novo Nordisk’s Ozempic, which is used to deal with sort 2 diabetes, and weight-loss drug Saxenda.
Shares of the Danish drugmaker had been barely increased on Monday afternoon, paring earlier losses.
A separate report from the BBC stated the EMA would additionally assessment Novo Nordisk’s Wegovy which, like Saxenda, is used to help weight-loss.
Each media shops stated the assessment would give attention to merchandise containing liraglutide or semaglutide. Saxenda’s lively ingredient is liraglutide. The lively ingredient in Wegovy and Ozempic is semaglutide.
Experiences of the probe come after the Icelandic Medicines Company notified the EMA of “three instances of sufferers on the medicine enthusiastic about suicide or self-harm,” Reuters stated.
In an announcement despatched to CNBC, Novo Nordisk stated, “Affected person security is a high precedence for Novo Nordisk, and we take all experiences about hostile occasions from use of our medicines very severely.”
“GLP-1 receptor agonists have been used to deal with sort 2 diabetes for greater than 15 years and for therapy of weight problems for 8 years, together with Novo Nordisk merchandise resembling semaglutide and liraglutide which have been in the marketplace for greater than 10 years,” it added.
“The protection knowledge collected from giant medical trial applications and submit advertising and marketing surveillance haven’t demonstrated a causal affiliation between semaglutide or liraglutide and suicidal and self-harming ideas.”
The enterprise stated that it was “repeatedly performing surveillance of the info from ongoing medical trials and real-world use of its merchandise and collaborates intently with the authorities to make sure affected person security and satisfactory data to healthcare professionals.”
“EMA repeatedly screens for security alerts and so does Novo Nordisk,” it stated. “Novo Nordisk stays assured within the profit threat profile of the merchandise and stays dedicated to making sure affected person security.”
The EMA was not instantly obtainable to remark when contacted by CNBC.
[ad_2]
Source link